Cite
HARVARD Citation
Moreno, V. et al. (n.d.). 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A395. [Online].